Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome

T. Wada, Y. Yoshikawa, Naohisa Yahagi, N. Kawamura, N. Kakei, Y. Matsubara, M. Tsuji, K. Miki

研究成果: Article

抄録

The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1% (13/22) and 68.2% (15/22), respectively. The rates in the final global improvement was 68.2% (15/22). The rates in the diarrhea and constipation predominant cases were 66.7% (12/18) and 75.0% (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0% (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.

元の言語English
ページ(範囲)219-232
ページ数14
ジャーナルJapanese Pharmacology and Therapeutics
26
発行部数SUPPL. 5
出版物ステータスPublished - 1998
外部発表Yes

Fingerprint

Irritable Bowel Syndrome
Safety
Constipation
Diarrhea
calcium polycarbophil
Clinical Studies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

これを引用

Wada, T., Yoshikawa, Y., Yahagi, N., Kawamura, N., Kakei, N., Matsubara, Y., ... Miki, K. (1998). Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. Japanese Pharmacology and Therapeutics, 26(SUPPL. 5), 219-232.

Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. / Wada, T.; Yoshikawa, Y.; Yahagi, Naohisa; Kawamura, N.; Kakei, N.; Matsubara, Y.; Tsuji, M.; Miki, K.

:: Japanese Pharmacology and Therapeutics, 巻 26, 番号 SUPPL. 5, 1998, p. 219-232.

研究成果: Article

Wada, T, Yoshikawa, Y, Yahagi, N, Kawamura, N, Kakei, N, Matsubara, Y, Tsuji, M & Miki, K 1998, 'Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome', Japanese Pharmacology and Therapeutics, 巻. 26, 番号 SUPPL. 5, pp. 219-232.
Wada T, Yoshikawa Y, Yahagi N, Kawamura N, Kakei N, Matsubara Y その他. Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. Japanese Pharmacology and Therapeutics. 1998;26(SUPPL. 5):219-232.
Wada, T. ; Yoshikawa, Y. ; Yahagi, Naohisa ; Kawamura, N. ; Kakei, N. ; Matsubara, Y. ; Tsuji, M. ; Miki, K. / Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome. :: Japanese Pharmacology and Therapeutics. 1998 ; 巻 26, 番号 SUPPL. 5. pp. 219-232.
@article{6886bc593c284fe7b7d089015475b18a,
title = "Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome",
abstract = "The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1{\%} (13/22) and 68.2{\%} (15/22), respectively. The rates in the final global improvement was 68.2{\%} (15/22). The rates in the diarrhea and constipation predominant cases were 66.7{\%} (12/18) and 75.0{\%} (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0{\%} (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0{\%} (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6{\%} (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.",
keywords = "Calcium polycarbophil, Constipation, Diarrhea, Fine granule, Gastrointestinal symptoms, Irritable bowel syndrome, Stool disorders",
author = "T. Wada and Y. Yoshikawa and Naohisa Yahagi and N. Kawamura and N. Kakei and Y. Matsubara and M. Tsuji and K. Miki",
year = "1998",
language = "English",
volume = "26",
pages = "219--232",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Clinical study of calcium polycarbophil fine granule on irritable bowel syndrome

AU - Wada, T.

AU - Yoshikawa, Y.

AU - Yahagi, Naohisa

AU - Kawamura, N.

AU - Kakei, N.

AU - Matsubara, Y.

AU - Tsuji, M.

AU - Miki, K.

PY - 1998

Y1 - 1998

N2 - The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1% (13/22) and 68.2% (15/22), respectively. The rates in the final global improvement was 68.2% (15/22). The rates in the diarrhea and constipation predominant cases were 66.7% (12/18) and 75.0% (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0% (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.

AB - The efficacy, safety and usefulness of calcium polycarbophil fine granule (HSR-237 G: 3.0 g/day) on irritable bowel syndrome (IBS) were investigated by open study. The number of cases in total was 26, that of the final global improvement rating was 22, the overall safety rating was 25 and the global utility rating was 22. In the global improvement ratings on gastrointestinal symptoms and stool disorders, the rates of cases assessed as 'moderately improved' or more were 59.1% (13/22) and 68.2% (15/22), respectively. The rates in the final global improvement was 68.2% (15/22). The rates in the diarrhea and constipation predominant cases were 66.7% (12/18) and 75.0% (3/4), respectively. The adverse reactions was not found. The rate of abnormal changes in clinical laboratory findings was 4.0% (1/25), which was slightly and not serious. The rate of the cases assessed as 'no problem in safety' in the overall safety rating was 96.0% (24/25). In the global utility rating, the rate of cases assessed as 'useful' or more was 63.6% (14/22). From above results, it was considered that calcium polycarbophil fine granule is very useful in the treatment of irritable bowel syndrome.

KW - Calcium polycarbophil

KW - Constipation

KW - Diarrhea

KW - Fine granule

KW - Gastrointestinal symptoms

KW - Irritable bowel syndrome

KW - Stool disorders

UR - http://www.scopus.com/inward/record.url?scp=0031791512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031791512&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031791512

VL - 26

SP - 219

EP - 232

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - SUPPL. 5

ER -